ADIAL PHARMACEUTICALS, INC. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
Adial Pharmaceuticals completed acquisition of Azora Therapeutics (adding AT177, a colon-targeted AhR agonist for ulcerative colitis) and closed initial $32 million tranche of up to $64 million private placement from biotech investors (including $5.5 million note conversion). Company pivot: from addiction-focused to autoimmune/inflammatory disease focus. Cash position improved to $28.7M as of June 30, 2026 from $4.6M on March 31, 2026; runway extended to second half 2027. Q2 2026 net loss was $52.0M ($11.25/share on 4.6M weighted-avg shares), primarily driven by $46.2M non-cash in-process R&D charge.
Why this rating
Acquisition + financing = ~5× market cap injected; strategic pivot material to tiny firm; cash provides 15-month runway; transformational repositioning with validated mechanism.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.